EU-Startups has learned that Dutch FemTech startup YON E Health has raised €250k in pre-Seed funding to develop a first-of-its-kind smart vaginal health device that measures pH and temperature, the key biomarkers for fertility, infection risk, and overall reproductive wellbeing.
The round was led by PMK-Group, with support from UniPrisma Venture Studio (Károly Szántó and Thijmen Meijer), who guided term sheet development and negotiation strategy, and Matias Toye, founder of Oyster Shield and Dilicheck, for M&A and fundraising support.
“When I started YON E, I was told vaginal health was too taboo, too complex, and too ‘niche’ for innovation and investment. That’s what motivated and pushed me even more,” said Roswitha Verwer, Founder and CEO.
This pre-Seed investment in YON E Health reflects the continued diversification of FemTech funding across Europe in 2025.
While YON E Health focuses on developing a smart vaginal health sensor for continuous monitoring of pH and basal body temperature, other startups in the women’s health space have also attracted investor attention.
UK-based Hormona secured €7.8 million to scale its hormone-tracking platform, and Solence in France raised €1.6 million to advance its AI-driven digital therapeutics for PCOS. At a later growth stage, SheMed closed a €43 million round to expand its personalised healthcare platform, while Unfabled grew its total funding to around €3 million for their women’s health platform.
Collectively, these rounds illustrate an active European market for women’s health technologies, spanning diagnostics, digital care, and retail solutions. YON E Health’s raise sits at the earliest end of this spectrum, positioning it within a wider trend toward combining clinical-grade data with accessible, user-centred hardware in the FemTech landscape.
“For too long, women have had to guess, self-diagnose, or wait until they show symptoms and something goes wrong with their health. We’re changing that, turning silence into data women can actually use,” added Verwer.
Founded by Roswitha Verwer in 2022, YON E Health is addressing what they call one of the most persistent gaps in women’s healthcare: the lack of accessible, real-time data concerning vaginal health.
Its first product is an at-home medical device for continuous pH and basal body temperature monitoring. The device is designed to give women accurate, science-backed insights into fertility, infection risk, and vaginal wellness.
YON E Health operates globally, with a multidisciplinary team spanning Amsterdam, Budapest, London, Texas, Boston, and Madrid, representing a new generation of innovators in women’s health.
“Vaginal health isn’t a luxury; it’s a foundation of overall wellbeing,” adds Dr Muskaan Bhan, Chief Clinical Officer at YON E Health. “Our technology bridges the gap between research and reality, empowering women globally with real-time, clinical-grade insights that can prevent complications before they start.”
Despite affecting half the global population, women’s health remains one of the most underfunded areas in medicine. According to data provided by the company, less than 1% of global medical research funding goes toward conditions specific to women, and in 2024, only 2.3% of venture capital funding reached female-founded startups.
This lack of resources has slowed innovation in areas like vaginal health, fertility, and menopause.
This pre-Seed round provides the start-up with the resources needed to accelerate preparations for medical trials. Key steps toward bringing YON E Health’s device into clinical and consumer use.
Vaginal pH is a core indicator of reproductive and gynecological health. An imbalance in vaginal acidity can signal everything from infection risk, such as Bacterial Vaginosis or yeast infection, to fertility and hormonal shifts.
Despite being a key indicator of women’s health, at-home pH measurement is currently conducted through one-time paper strip tests, often used only after symptoms appear, leaving treatment reactive instead of proactive.
YON E Health’s sensor technology enables at-home measurement of vaginal pH and basal body temperature simultaneously, providing women and clinicians with visibility into menstrual cycle patterns, microbiome health, and fertility windows.
The data can help detect early warning signs of imbalance, optimise conception timing, and even support diagnosis in fertility or recurrent infection cases.
“YON E Health is addressing an area that’s both underserved and scientifically critical,” said Dr Peter M. Kovacs. “Their approach, combining biosensor technology, clinical expertise, and user empathy, represents the future of proactive care in women’s health.”
Read the orginal article: https://www.eu-startups.com/2025/11/amid-just-2-3-of-vc-capital-going-to-female-founders-yon-e-health-secures-e250k-for-its-vaginal-health-device/
